PharmTech LCGC Sciex Webinar 11.10
|Articles|January 10, 2007

Novasep Acquisition by its Management and by Gilde, Banexi, BNP Paribas has Been Signed

Groupe Novasep has been acquired for an enterprise value ofEUR 425 million by its management and by a financial investor group composedof Gilde Buy Out, Banexi Capital Partenaires, BNP Paribas. The acquisitionhas been signed on November 29th, 2006 and completed on January 9th 2007.

Groupe Novasep has been acquired for an enterprise value ofEUR 425 million by its management and by a financial investor group composedof Gilde Buy Out, Banexi Capital Partenaires, BNP Paribas. The acquisitionhas been signed on November 29th, 2006 and completed on January 9th 2007.

Groupe Novasep will continue to operate through two complementarydivisions contributing to approximately EUR 280 million of sales. NovasepSynthesis offers custom synthesis services utilising niche technologies toproduce elaborate molecules for the pharmaceutical industry, as well asproducing and marketing proprietary products, typically generics.Novasep Process is a recognised leader in the field of chromatography, withparticular strength in continuous processes. It provides turn-key physicalpurification solutions to industrial biotech, pharmaceutical and the growingbio-pharma industries. Headquartered in Pompey (France), Novasep operatesmainly in Europe, with subsidiaries in the United States, China and Japan and1300 employees working in nine sites.


Related to this article

Best of the Week: From Cancer Diagnostics to Smarter LC Method Development
This week, Chromatography Online’s coverage spanned lipidomics-based early cancer detection, career paths in separation science, machine learning and uncertainty-driven approaches to LC method development, new EU wastewater rules for pharmaceutical micropollutants, automated Separation Quality Factor (SQF) evaluation in chromatography data systems, and solutions to GLP-1 peptide analysis challenges.